leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...919293949596979899100101...235236»
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical data, Journal, Heterogeneity:  Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer. (Pubmed Central) -  May 15, 2022   
    Here, we explore ctDNA-based heterogeneity and its correlation with treatment outcome in STEAM, which assessed efficacy and safety of concurrent and sequential FOLFOXIRI-bevacizumab (BEV) vs. FOLFOX-BEV for first-line treatment of metastatic colorectal cancer...Patients with high MATH vs. low MATH in post-induction plasma had shorter PFS (7.2 vs. 11.7 months; hazard ratio, 3.23; 95% confidence interval, 1.85-5.63; log-rank p < 0.0001). These results suggest ctDNA-based tumor heterogeneity may have potential prognostic value in metastatic cancers.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Preclinical, Journal:  Short-duration Aerobic Exercise Improves Chemotherapy Induced Physical Dysfunction in Mice. (Pubmed Central) -  May 14, 2022   
    Two weeks of short-duration aerobic exercise was sufficient to reverse chemotherapy induced fatigue without improving strength. Future studies should examine if the combined effects of aerobic and resistance exercise can improve strength.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Chemotherapy Drugs Induce Cachexia and Alter Muscle Protein Metabolism. (Pubmed Central) -  May 14, 2022   
    Findings from this study will help to elucidate whether unique signatures of cachexia are experienced in older mice. Better understanding of the mechanisms underlying muscle mass regulation following chemotherapy treatment may help combat cachexia.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    INTENDED USE OF GLUCARPIDASE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND IMPAIRED RENAL FUNCTION – THE VALIDATE STUDY () -  May 13, 2022 - Abstract #EHA2022EHA_1018;    
    The pharmacological efficacy of Glucarpidase will be assessed by determining the immediate and sustained reduction of MTX plasma concentrations after Glucarpidase administration, in addition to leucovorin...Study pts may receive up to 6 cycles of HD-MTX (additional Rituximab prior HD-MTX is allowed as standard of care treatment) at MTX dose levels of 3.0 or 3.5 or 4.0 g/m 2 body surface area administered over 4 hours (6 pts per dose level)...However, the available data are currently limited and the first HD-MTX escalation step has not yet been reached. The observed hypersensitivity reactions are possibly due to antibody formation, which will be further investigated and prophylactic measures at least beyond the first treatment cycle will be considered.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date:  Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  May 12, 2022   
    P1,  N=36, Recruiting, 
    This will allow better counseling of patients with regards to the benefits of treatment, improved stratification within clinical trials, and potentially identify groups of patients for novel therapy trials as first-line treatment. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2022 --> Apr 2023
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Total neoadjuvant therapy (TNT) in early-onset (EO) vs average-onset (AO) locally advanced rectal cancer (LARC): Patient characteristics and tolerance (Auditorium A; Level 0) -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_512;    
    Patients with EO (< 50 years of age) colorectal cancer (CRC) have been shown to have significantly more nausea and vomiting with adjuvant fluoropyrimidine and oxaliplatin compared to patients with AO (≥50 years) CRC...These findings are consistent with adjuvant chemotherapy outcomes in EOCRC. Further data will be presented on the timing of nausea in order to optimize treatment for patients with EORC.
  • ||||||||||  oxaliplatin / Generic mfg.
    Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer (Auditorium B; Level 0) -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_509;    
    Adjuvant treatment is not established in stage II CC where leucovorin-5FU (FU) has a limited efficacy and oxaliplatin (OX) may have some benefit in high-risk (HR) stage II CC...OX is not the standard of care in adjuvant therapy of stage II CC based on clinical factors. Further studies should focus on new biomarkers like circulating tDNA to better identify the risk and the potential benefit of adjuvant therapy.
  • ||||||||||  Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma (Auditorium A; Level 0) -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_488;    
    Among KRAS-WT PDAC, more than one third of the patients had a potentially actionable molecular alteration and 15% received a treatment targeting a molecular anomaly of interest. Patients without KRAS mutations should be eligible for broad molecular screening in a precision medicine approach.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a case series () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_442;    
    Our aim is to evaluate the progression-free survival (PFS) of genetically unselected patients with locally advanced or metastatic pancreatic cancer, who received maintenance therapy following good response to induction chemotherapy with FOLFIRINOX (Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Oxaliplatin)...Conclusions Emerging studies are supporting the use of maintenance therapy in metastatic and advanced pancreatic cancer. Although our study is limited by its small sample size, the results are promising and encourage further exploration of this topic in larger prospective trials.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    The prevalence of pancreatic cancer-associated thrombosis in Mexican patients () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_421;    
    Until today, even though chemotherapy combinations (FOLFIRINOX) or targeted therapies (like PARP inhibitors), the prognosis remains poor...Overall survival was not different between patients with or without thrombosis, but this was not true for progression-free survival. Certainly, very few patients receive prophylaxis, and it may be related to the lack of correct identification of the patient at risk coupled with the high cost of low molecular weight heparin or direct oral anticoagulants.
  • ||||||||||  irinotecan / Generic mfg.
    Тoxicity and tolerability of the mFOLFIRINOX regimen in young elderly and older elderly patients with pancreatic carcinoma (PC) () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_391;    
    Methods We retrospectively analyzed the data of patients with PC 60 years and older who were treated with mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, 5FU 2400 mg/m2 for 46h) regimen in our center...Methods We retrospectively analyzed the data of patients with PC 60 years and older who were treated with mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, 5FU 2400 mg/m2 for 46h) regimen in our center...Tolerability didn't differ between ECOG status. mFOLFIRINOX regimen is tolerable and demonstrates manageable toxicity in selected elderly patients with pancreatic carcinoma.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    FOLFIRI as third- or later-line treatment for advanced biliary tract cancer in Northern Thailand () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_385;    
    Background The combination of gemcitabine and cisplatin, and FOLFOX (fluorouracil and oxaliplatin) are recognized as the standard first- and second-line chemotherapy regimen in advanced biliary tract cancer (BTC)...Exploratory analysis was performed to define possible prognostic factors related to OS. Conclusions Though activity in late-line treatment of advanced BTC with FOLFIRI is modest and associated with significant toxicities, further studies with dose modification are warranted in patients with BTC refractory to standard chemotherapy and novel treatment inaccessible.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Circulating tumor DNA as a prognostic biomarker in pancreatic cancer patients treated with FOLFIRINOX: A prospective cohort study () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_363;    
    P=N/A
    Tumor tissue expression of hENT1, DCK, CES2, and SMAD4 were evaluated by immunohistochemistry, which biomarkers were reported to predict the response to gemcitabine or FOLFIRINOX chemotherapies...Conclusions The preliminary results suggest that high pre-treatment KRAS mutation was associated with a negative impact on survival in patients with FOLFIRINOX. Further investigations are warranted.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Anti-EGFR antibodies may get benefit as first-line treatment in metastatic right-sided colon cancer () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_349;    
    Conclusions Right sided mCRC with combined RAS/RAF wild &Her2+ve &VEGF -ve expression did not benefitted from chemotherapy plus anti-VEGF as first-line setting so, we suggest that this group of patients may benefit from chemotherapy plus anti EGFR antibodies ± Her2 target therapy in first-line setting and this could be proven in future works that could help in risk adapted therapy. The primary tumor sidedness may not the only surrogate marker for selecting first-line targeted therapy in mCRC.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16 () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_274;    
    Methods The JACCRO CC-16 was a single arm, phase 2 trial to evaluate the efficacy and safety of RAM (8 mg/kg) plus FOLFIRI (irinotecan 150 mg/m2, bolus 5-FU 400 mg/m2, infusional 5-FU 2400 mg/m2) in mCRC patients with RAS wild-type tumors and ECOG PS 0 or 1, after 1st-line oxaliplatin-based doublet (Ox-doublet) or triplet plus anti-EGFR antibody...Conclusions This study demonstrated a favorable efficacy of FOLFIRI plus RAM treatment in RAS wild-type mCRC patients treated with 1st-line anti-EGFR antibody-containing therapy. It may also achieve a certain effect in cases previously treated with triplet-based regimen.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Stivarga (regorafenib) / Bayer
    Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy () -  May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_248;    
    These tumoroids were added to pre-loaded gel arrays containing the drugs of interest (FOLFOX, FOLFIRI, FOLFOXIRI, regorafenib, trifluridine + tipiracil, mitomycin C + 5FU, gemcitabine + 5FU, temozolomide + irinotecan)...Conclusions IndiTreat® provides an individual drug sensitivity profile that clearly differentiated between "low sensitivity" and "high sensitivity" tumoroids for each drug in the panel. This information can be used by oncologists to determine if any of the treatments indicated in guidelines can be an option for that patient, or if she might benefit from the off-label use of certain drugs, thus expanding their treatment options and achieving the benefits of personalization even with standard chemotherapy regimens.